The Structured Interview for the Treatment of the Hepatitis C Virus (SIT-HCV)

  • Amy K. Silberbogen
  • DeAnna L. Mori
  • Stephanie Sogg
Original Article


The purpose of this paper is to introduce the Structured Interview for the Treatment of the Hepatitis C Virus (SIT-HCV). This comprehensive interview expands upon a standard psychiatric interview by including those medical, psychological, and behavioral factors that are essential to determining a patient’s psychological appropriateness for interferon therapy. A detailed description of the SIT-HCV is provided, highlighting its utility in developing recommendations that positively impact patients’ treatment outcomes. The advantages of the SIT-HCV will be presented, including a discussion on how this approach can ensure comprehensive assessment and facilitate research, training, and patient education.

hepatitis C virus interferon treatment psychological evaluation medical outcomes 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Beck, A. T., Ward., C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry, 4, 561–571.Google Scholar
  2. Bianchi, G., Loguercio, C., Sgarbi, D., Abbiati, R., Chen, C. H., DiPierro, M., (2000). Reduced quality of life in patients with chronic hepatitis C: Effects of interferon treatment. Digestive and Liver Disease, 32, 398–405.Google Scholar
  3. Booth, J. C., O’Grady, J., & Neuberger, J. (2001). Clinical guidelines on the management of hepatitis C. Gut, 49, 1–21.Google Scholar
  4. Butcher, J. N., Dahlstrom, W. G., Graham, J. R., & Kaemmer, B. (1989). Manual for the restandardization of the Minnesota Multiphasic Personality Inventory: MMPI—2, an interpretive and administrative guide. Minneapolis, MN, University of Minnesota Press.Google Scholar
  5. Carver, C. S., Scheier, M., & Weintraub, J. K. (1989). Assessing coping strategies: A theoretically based approach. Journal of Personality and Social Psychology, 56, 267–283.Google Scholar
  6. Coughlan, B., Sheehan, J., Hickey, A., & Crowe, J. (2002). Psychological well-being and quality of life in women with an iatrogenic hepatitis C virus infection. British Journal of Health Psychology, 7, 105–116.Google Scholar
  7. Crone, C., & Gabriel, G. M. (2003). Comprehensive review of hepatitis C for psychiatrists: Risks, screening, diagnosis, treatment, and interferon-based therapy complications. Journal of Psychiatric Practice, 9, 93–110.Google Scholar
  8. Davis, G., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., (1989). Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial. New England Journal of Medicine, 321, 1501–1510.Google Scholar
  9. Davis, G., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., (1994). Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clinical Therapeutics, 16, 334–343.Google Scholar
  10. Detre, K. M., Belle, S. H., & Lombardero, M. (1996). Liver transplantation for chronic viral hepatitis. Viral Hepatitis Review, 2, 219–228.Google Scholar
  11. Dieperink, E., Willenbring, M., & Ho, S. B. (2000). Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. American Journal of Psychiatry, 157, 567–576.Google Scholar
  12. Falck-Ytter, Y., Hermangi, K., Mullen, K. D., Sarbah, S. A., Sorescu, L., & McCullough, A. J. (2002). Surprisingly small effect of antiviral treatment in patients with hepatitis C. Annals of Internal Medicine, 136, 288–292.Google Scholar
  13. Foster, G. R., Goldin, R. D., & Thomas, H. C. (1998). Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology, 27, 209–212.Google Scholar
  14. Ho, S. B., Nguyen, H., Tetrick, L. L., Opitz, G. A., Basara, M. L., Dieperink, E. (2001). Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. The American Journal of Gastroenterology, 96, 157–164.Google Scholar
  15. Kraus, M. R., Schafer, A., Csef, H., Faller, H., Mork, H., & Scheurlen, M. (2001). Compliance with therapy in patients with chronic hepatitis C: Association with psychiatric symptoms, interpersonal problems, and mode of acquisition. Digestive Diseases and Sciences, 46, 2060–2065.Google Scholar
  16. Lehman, C. L. (2001). Hepatitis C in veterans: The role of psychology in a multidisciplinary clinic. The Health Psychologist, 23, 17–21.Google Scholar
  17. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., (2001). Peginterferon alfa-2b in combination with ribavirin compared to interferon alfa2b plus ribavirin for initial treatment of chronic hepatitis C: Results of a randomized trial. Lancet, 358, 958–965.CrossRefGoogle Scholar
  18. McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine, 339, 1485–1492.Google Scholar
  19. Mori, D. L., Gallagher, P., Milne, J. (2000). The structured interview for rental transplantation—SIRT. Psychosomatics, 41, 393–406.Google Scholar
  20. Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., (1998). Randomised trial of interferon alpha 2b plus ribavirin for 49 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. The Lancet, 352, 1426–1432.Google Scholar
  21. Satcher, D. (2000). Hepatitis C: Education campaign. Retrieved on July 15, 2004 from hepatitisc/default.htmGoogle Scholar
  22. Terrault, N. A. (2000). Hepatitis C virus and liver transplantation. Seminars in Gastrointestinal Disease, 11, 96–114.Google Scholar
  23. Vallis, T. M., Peltekian, K., & Hitsch, G. (2003). Fatigue and quality of life in hepatitis C: Fact or fiction? Journal of Clinical Psychology in Medical Settings, 10, 267–271.Google Scholar
  24. Wallston, K. A., Wallston, B. S., DeVellis, R. (1978). Development of the multidimensional health locus of control (MHLC) scales. Health Education Monographs, 6, 160–170.Google Scholar
  25. Yovtcheva, S. P., Rifal, M. A., Moles, J. K., & Van Der Linden, B. (2001). Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics, 42, 411–415.Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Amy K. Silberbogen
    • 1
    • 3
  • DeAnna L. Mori
    • 1
  • Stephanie Sogg
    • 2
  1. 1.VA Boston Healthcare System and Boston University School of MedicineBoston
  2. 2.The Massachusetts General Hospital Weight Center and Harvard Medical SchoolBoston
  3. 3.VA Boston Healthcare System, Psychology (116B)Boston

Personalised recommendations